Fujisawa Pharmaceutical Company, Ltd.

Hiroki Ono

Ikuo Ueda

Hitoshi Kojo

Mineo Niwa

Tadashi Kitaguchi

Masakazu Kobayashi

Takao Isogai

Yoshimasa Saito

Morita Iwami

Masao Fukagawa

Ichiro Aramori

Hisashi Yamada

Susumu Sato

Yosuke Ishitani

Mana Tsumura

Susumu Satoh

Masato Kitayama

Masaru Hayashi

Masaru Ohnishi

Kazuo Ohkawa

Yoshimasa Saitoh

Chihiro Kusunoki

This invention provides a novel industrial process for preparation of an anhydride of 2-(2-aminothiazole-4-yl)-2-hydroxy compound.

Process for producing anhydride of aminothiazole derivative

D-amino acid oxidase (DAO) originated from Fusarium solani M-0718, a DNA compound encoding the oxidase, expression vectors containing said DNA compound are provided. Esherichia coli transformants capable of producing recombinant DAO in high level are also provided.

D-amino acid oxidase of F. solani and methods for its recombinant

D-amino acid oxidase from F. solani and DNA therefor

A GL-7ACA acylase having the following characteristics:

GL-7ACA acylase

IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

IGF-I fusion proteins; protection of IGF-I from degradation by host

IGF-I fusion proteins; protection of IGF-I from degradation by host cell

The present invention relates to a .sup.59 Valine insulin-like growth factor I (.sup.59 Val.IGF-I), to a .sup.59 Val-IGF-I fused to a protective peptide, to a gene coding for .sup.59 Val-IGF-I, to a gene coding for fused .sup.59 Val-IGF-I, to a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the fused .sup.59 Val-IGF-I gene, and to processes for the production of these.

.sup.59 Valine insulin-like growth factor I and process for production

7-Amino-2 or 3-cephem-4-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is amino; R.sup.2 is carboxy or carboxy protected by a pharmaceutically acceptable group; ##STR2## is di(lower)alkylamino(lower)alkylamino, an unsaturated or saturated 3 to 8 membered heteromonocyclic(lower)alkylamino group containing 1 to 4 nitrogen atoms, an unsaturated or saturated 3 to 8 membered heteromonocyclic(lower)alkylamino group containing 1 to 4 nitrogen atoms substituted by lower alkyl orhydroxy(lower)alkyl, an unsaturated or saturated 5 to 6 membered heteromonocyclic group containing 2 to 4 nitrogen atoms, an unsaturated or saturated 5 to 6 membered heteromonocyclic group containing 2 to 4 nitrogen atoms substituted by lower alkyl or hydroxy(lower)alkyl or hydroxypiperidino, and X is --S or ##STR3## and pharmaceutically acceptable salts thereof.

3,7-Disubstituted-2 or 3-cephem-4-carboxylic acid compounds

3,7-Disubstituted-2 or 3-cephem-4-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is acylamino or ar(lower)alkylamino; R.sup.2 is carboxy or carboxy protected by a pharmaceutically acceptable group; --N--R.sup.3, R.sup.4 is di(lower)alkylamino(lower)alkylamino, an unsaturated or saturated 3 to 8 membered heteromonocyclic (lower)alkylamino group containing 1 to 4 nitrogen atoms, an unsaturated or saturated 3 to 8 membered heteromonocyclic (lower)alkylamino group containing 1 to 4 nitrogen atoms substituted by lower alkyl or hydroxy(lower) alkyl, an unsaturated or saturated 5 to 6 membered heteromonocyclic group containing 2 to 4 nitrogen atoms, an unsaturated or saturated 5 to 6 membered heteromonocyclic group containing 2 to 4 nitrogen atoms substituted by lower alkyl or hydroxy(lower)alkyl or hydroxypiperidino, and X is --S-- or ##STR2## and pharmaceutically acceptable salts thereof. The present compounds are useful for the treatment of infectious diseases in animals and human beings.

Growing community of inventors

Osaka, Japan

Hiroki Ono